111 related articles for article (PubMed ID: 9468640)
1. Studies on agents with vasodilator and beta-blocking activities. V. Synthesis and pharmacological activity of the optical isomers of TZC-5665.
Seki T; Kanada A; Nakao T; Shiraiwa M; Asano H; Miyazawa K; Ishimori T; Minami N; Shibata K; Yasuda K
Chem Pharm Bull (Tokyo); 1998 Jan; 46(1):84-96. PubMed ID: 9468640
[TBL] [Abstract][Full Text] [Related]
2. Studies on agents with vasodilator and beta-blocking activities. III. Synthesis and activity of optical isomers of TZC-1370.
Seki T; Takezaki T; Ohuchi R; Saitoh M; Ishimori T; Yasuda K
Chem Pharm Bull (Tokyo); 1995 Oct; 43(10):1719-23. PubMed ID: 8536346
[TBL] [Abstract][Full Text] [Related]
3. Studies on agents with vasodilator and beta-blocking activities. I.
Seki T; Takezaki T; Ohuchi R; Ohuyabu H; Ishimori T; Yasuda K
Chem Pharm Bull (Tokyo); 1994 Aug; 42(8):1609-16. PubMed ID: 7954913
[TBL] [Abstract][Full Text] [Related]
4. Studies on agents with vasodilator and beta-blocking activities. IV.
Seki T; Nakao T; Masuda T; Hasumi K; Gotanda K; Ishimori T; Honma S; Minami N; Shibata K; Yasuda K
Chem Pharm Bull (Tokyo); 1996 Nov; 44(11):2061-9. PubMed ID: 8945771
[TBL] [Abstract][Full Text] [Related]
5. Studies on agents with vasodilator and beta-blocking activities. II.
Seki T; Takezaki T; Ohuchi R; Ohuyabu H; Tanimoto Y; Yamaguchi T; Saitoh M; Ishimori T; Yasuda K
Chem Pharm Bull (Tokyo); 1995 Feb; 43(2):247-55. PubMed ID: 7728931
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of the four stereoisomers of 6-[4-[3-[[2-hydroxy-3-[4-[2- (cyclopropylmethoxy)ethyl]phenoxy]propyl]amino]-propionamido] phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone, a combined vasodilator and beta-adrenoceptor antagonist.
Howson W; Kitteringham J; Mistry J; Mitchell MB; Novelli R; Slater RA; Swayne GT
J Med Chem; 1988 Feb; 31(2):352-6. PubMed ID: 2892935
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of a series of combined vasodilator/beta-adrenoceptor antagonists based on 6-arylpyridazinones.
Slater RA; Howson W; Swayne GT; Taylor EM; Reavill DR
J Med Chem; 1988 Feb; 31(2):345-51. PubMed ID: 2892934
[TBL] [Abstract][Full Text] [Related]
8. Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.
Sircar I; Steffen RP; Bobowski G; Burke SE; Newton RS; Weishaar RE; Bristol JA; Evans DB
J Med Chem; 1989 Feb; 32(2):342-50. PubMed ID: 2536438
[TBL] [Abstract][Full Text] [Related]
9. Studies on new beta-adrenergic blocking agents. II. Syntheses and pharmacology of 2-anilinotropone derivatives.
Sato Y; Tanaka T; Kumakura S; Koike H; Oshima T
Chem Pharm Bull (Tokyo); 1974 Mar; 22(3):514-22. PubMed ID: 4153810
[No Abstract] [Full Text] [Related]
10. [Levosimendan].
Michels G; Herzig S; Hoppe UC
Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
[No Abstract] [Full Text] [Related]
11. An approach to peripheral vasodilator-beta-adrenergic blocking agents.
Baldwin JJ; Hirschmann R; Lumma PK; Lumma WC; Ponticello GS; Sweet CS; Scriabine A
J Med Chem; 1977 Aug; 20(8):1024-9. PubMed ID: 19628
[TBL] [Abstract][Full Text] [Related]
12. Cardiac effects of the novel pyridazinone derivative 6-[4-[2-[3-(5-chloro-2-cyanophenoxy)-2-hydroxypropylamino]- 2- methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H) pyridazinone monoethyl maleate and its metabolite in isolated heart preparations of guinea pigs and dogs.
Ishimori T; Gotanda K; Sasaki T; Shinbo A; Asano H; Miyazawa K; Miyasaka K
Arzneimittelforschung; 1994 May; 44(5):583-8. PubMed ID: 7912931
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive and vasorelaxing activities of synthetic xanthone derivatives.
Wang LW; Kang JJ; Chen IJ; Teng CM; Lin CN
Bioorg Med Chem; 2002 Mar; 10(3):567-72. PubMed ID: 11814844
[TBL] [Abstract][Full Text] [Related]
14. 4,5-disubstituted pyridazin-3(2H)-ones as hypotensive drugs: incorporation of a beta-blocking moiety.
Gómez-Gil MC; Gómez-Parra V; Sánchez F; Torres T
Arch Pharm (Weinheim); 1986 Jan; 319(1):60-4. PubMed ID: 2870697
[No Abstract] [Full Text] [Related]
15. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
Duncker DJ; Verdouw PD
Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
[No Abstract] [Full Text] [Related]
16. Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agents.
Baldwin JJ; Lumma WC; Lundell GF; Ponticello GS; Raab AW; Engelhardt EL; Hirschmann R; Sweet CS; Scriabine A
J Med Chem; 1979 Nov; 22(11):1284-90. PubMed ID: 42797
[No Abstract] [Full Text] [Related]
17. Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities.
Amin EN; Abdel-Alim AA; Abdel-Moty SG; El-Shorbagi AN; Abdel-Rahman MSh
Arch Pharm Res; 2010 Jan; 33(1):25-46. PubMed ID: 20191341
[TBL] [Abstract][Full Text] [Related]
18. [Combination therapy with PDE III inhibitor for heart failure].
Watanabe H; Kajimoto K; Kawana M
Nihon Rinsho; 2007 May; 65 Suppl 5():134-9. PubMed ID: 17571377
[No Abstract] [Full Text] [Related]
19. Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents.
Gouault N; Martin-Chouly CA; Lugnier C; Cupif JF; Tonnelier A; Feger F; Lagente V; David M
J Pharm Pharmacol; 2004 Aug; 56(8):1029-37. PubMed ID: 15285848
[TBL] [Abstract][Full Text] [Related]
20. Pyridazinone derivatives: design, synthesis, and in vitro vasorelaxant activity.
Abouzid K; Abdel Hakeem M; Khalil O; Maklad Y
Bioorg Med Chem; 2008 Jan; 16(1):382-9. PubMed ID: 17905589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
